Biohaven (BHVN) vs Ultragenyx Pharmaceutical (RARE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Biohaven (BHVN) has outperformed Ultragenyx Pharmaceutical (RARE) over the past year, losing 29.9% versus a loss of 51.1%. Biohaven is the larger company by market cap ($1.82 billion vs $1.53 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHVN | RARE |
|---|---|---|
| Share price | $12.08 | $15.48 |
| Market cap | $1.82B | $1.53B |
| 1-day change | +1.26% | +1.24% |
| YTD return | +7.00% | -32.70% |
| 1-year return | -29.89% | -51.11% |
| 5-year return | — | -80.65% |
| Forward P/E | — | 22.87 |
| EPS (TTM) | $-4.62 | $-5.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $673.00M |
| Revenue growth (YoY) | — | +20.18% |
| Net income (latest FY) | $-738.82M | $-575.00M |
| Operating margin | — | -79.49% |
| Net margin | — | -85.44% |
| 52-week high | $18.57 | $39.89 |
| 52-week low | $7.48 | $12.73 |
| Distance from 52-week high | -34.93% | -61.19% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +76.08% | +73.06% |
| Average volume | 2.63M | 3.90M |
| Shares outstanding | 151.04M | 98.59M |
| Employees | 274 | 1,371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BHVN has outperformed RARE by 21.2 percentage points over the past year.
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
About Ultragenyx Pharmaceutical
RARE stock →Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees
BHVN vs RARE FAQ
Which is bigger, Biohaven or Ultragenyx Pharmaceutical?
Biohaven (BHVN) is larger, with a market capitalization of $1.82B compared with $1.53B for Ultragenyx Pharmaceutical (RARE).
Which stock has performed better over the past year, BHVN or RARE?
BHVN returned -29.89% over the past 12 months, compared with -51.11% for RARE (price return, excluding dividends). Past performance does not predict future results.
Are Biohaven and Ultragenyx Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.